Glaucoma is the leading cause of blindness and is often related to high intraocular pressure. However, over 10% have progressive visual loss despite optimal intraocular pressure lowering. Our drugs are proven to reduce visual loss in mouse studies. Non-human primate studies are pending, and human trials should begin in 2025.
The Seed Raise is fully subscribed and has officially been closed
The Series A Raise will open in early 2024
Subscribe to the mailing list to be notified.
MD Anderson Cancer Center
Marion Merrell Dow, Neurocrine,
Cytovia, Molecular Therapeutics,
Molecular Imaging Research
NuFund Venture Group
Emergency Physician – Retired
Scripps Memorial Hospital – La Jolla
NuFund Venture Group
Professor, Department of Ophthalmology
University of Colorado School of Medicine
Walgreens Boots Alliance
NuFund Venture Group
Sign up to receive updates, news, and more.
Eyegenex
A San Diego Pharmaceutical Company
Copyright © 2023 Eyegenex - All Rights Reserved.